Halozyme Therapeutics, Inc.

Symbol: 0J2O.L

LSE

43.365

USD

Market price today

  • 19.8741

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 5.35B

    MRK Cap

  • 0.00%

    DIV Yield

Halozyme Therapeutics, Inc. (0J2O-L) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.68%

Operating Profit Margin

0.41%

Net Profit Margin

0.34%

Return on Assets

0.16%

Return on Equity

2.05%

Return on Capital Employed

0.21%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO:Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Full-time employees:373
City:San Diego
Address:11388 Sorrento Valley Road
IPO:2018-01-29
CIK:

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.679% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.407%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.340%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.162% return, is a testament to Halozyme Therapeutics, Inc.'s adeptness in optimizing resource deployment. Halozyme Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 2.048%. Furthermore, the proficiency of Halozyme Therapeutics, Inc. in capital utilization is underscored by a remarkable 0.208% return on capital employed.

Stock Prices

Halozyme Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $39.41, while its low point bottomed out at $39.41. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Halozyme Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing 0J2O.L liquidity ratios reveals its financial health of the firm. The current ratio of 663.52% gauges short-term asset coverage for liabilities. The quick ratio (506.88%) assesses immediate liquidity, while the cash ratio (105.22%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio663.52%
Quick Ratio506.88%
Cash Ratio105.22%

Profitability Ratios

0J2O.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 42.01% underscores its earnings before tax deductions. The effective tax rate stands at 19.16%, revealing its tax efficiency. The net income per EBT, 80.84%, and the EBT per EBIT, 103.19%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 40.71%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin42.01%
Effective Tax Rate19.16%
Net Income per EBT80.84%
EBT per EBIT103.19%
EBIT per Revenue40.71%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 6.64, it details the span from stock purchase to revenue. The 5 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 354.06% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding507
Days of Inventory Outstanding175
Operating Cycle278.09
Days of Payables Outstanding16
Cash Conversion Cycle262
Receivables Turnover3.54
Payables Turnover22.52
Inventory Turnover2.09
Fixed Asset Turnover11.06
Asset Turnover0.48

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 3.01, and free cash flow per share, 2.89, depict cash generation on a per-share basis. The cash per share value, 2.60, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.47, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share3.01
Free Cash Flow per Share2.89
Cash per Share2.60
Operating Cash Flow Sales Ratio0.47
Free Cash Flow to Operating Cash Flow Ratio0.96
Cash Flow Coverage Ratio0.25
Short Term Coverage Ratio12.07
Capital Expenditure Coverage Ratio25.41
Dividend Paid and Capex Coverage Ratio25.41

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 88.36%, highlights its total liabilities relative to assets. With a debt-equity ratio of 18.27, we discern the balance between debt and equity financing. The long-term debt to capitalization, 94.71%, and total debt to capitalization, 94.81%, ratios shed light on its capital structure. An interest coverage of 17.99 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio88.36%
Debt Equity Ratio18.27
Long Term Debt to Capitalization94.71%
Total Debt to Capitalization94.81%
Interest Coverage17.99
Cash Flow to Debt Ratio0.25
Company Equity Multiplier20.68

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 6.29, provides a glimpse into top-line earnings distributed across each share. Net income per share, 2.13, reflects the portion of profit attributed to each share. The book value per share, 0.64, represents the net asset value distributed per share, while the tangible book value per share, -6.11, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share6.29
Net Income Per Share2.13
Book Value Per Share0.64
Tangible Book Value Per Share-6.11
Shareholders Equity Per Share0.64
Interest Debt Per Share11.75
Capex Per Share-0.12

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 25.62%, indicates top-line expansion, while the gross profit growth, 17.89%, reveals profitability trends. EBIT growth, 16.63%, and operating income growth, 16.63%, offer insights into operational profitability progression. The net income growth, 39.31%, showcases bottom-line expansion, and the EPS growth, 43.92%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth25.62%
Gross Profit Growth17.89%
EBIT Growth16.63%
Operating Income Growth16.63%
Net Income Growth39.31%
EPS Growth43.92%
EPS Diluted Growth45.83%
Weighted Average Shares Growth-3.59%
Weighted Average Shares Diluted Growth-4.56%
Operating Cash Flow Growth61.83%
Free Cash Flow Growth58.64%
10-Year Revenue Growth per Share1193.92%
5-Year Revenue Growth per Share493.74%
3-Year Revenue Growth per Share219.94%
10-Year Operating CF Growth per Share773.40%
5-Year Operating CF Growth per Share953.53%
3-Year Operating CF Growth per Share623.44%
10-Year Net Income Growth per Share388.43%
5-Year Net Income Growth per Share481.16%
3-Year Net Income Growth per Share125.22%
10-Year Shareholders Equity Growth per Share458.48%
5-Year Shareholders Equity Growth per Share-63.39%
3-Year Shareholders Equity Growth per Share-42.72%
Receivables Growth1.36%
Inventory Growth27.44%
Asset Growth-5.88%
Book Value per Share Growth-48.80%
Debt Growth1.68%
R&D Expense Growth14.65%
SGA Expenses Growth22.66%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 6,281,181,263.1, captures the company's total value, considering both debt and equity. Income quality, 1.38, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 51.33%, indicates the value of non-physical assets, and capex to operating cash flow, -3.94%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value6,281,181,263.1
Income Quality1.38
Research and Development to Revenue9.21%
Intangibles to Total Assets51.33%
Capex to Operating Cash Flow-3.94%
Capex to Revenue-1.84%
Capex to Depreciation-18.02%
Stock-Based Compensation to Revenue4.42%
Graham Number5.52
Return on Tangible Assets33.38%
Graham Net Net-8.14
Working Capital633,930,000
Tangible Asset Value-805,892,000
Net Current Asset Value-903,038,000
Invested Capital18
Average Receivables232,641,000
Average Payables14,754,500
Average Inventory113,862,000
Days Sales Outstanding103
Days Payables Outstanding16
Days of Inventory On Hand175
ROIC16.90%
ROE3.36%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 66.78, and the price to book ratio, 66.78, reflect the market's valuation relative to the company's book value. The price to sales ratio, 6.22, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 13.82, and price to operating cash flows, 14.40, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio66.78
Price to Book Ratio66.78
Price to Sales Ratio6.22
Price Cash Flow Ratio14.40
Enterprise Value Multiple8.87
Price Fair Value66.78
Price to Operating Cash Flow Ratio14.40
Price to Free Cash Flows Ratio13.82
Price to Tangible Book Ratio58.09
Enterprise Value to Sales7.57
Enterprise Value Over EBITDA14.87
EV to Operating Cash Flow16.16
Earnings Yield5.78%
Free Cash Flow Yield7.67%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Halozyme Therapeutics, Inc. (0J2O.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 19.874 in 2024.

What is the ticker symbol of Halozyme Therapeutics, Inc. stock?

The ticker symbol of Halozyme Therapeutics, Inc. stock is 0J2O.L.

What is company IPO date?

IPO date of Halozyme Therapeutics, Inc. is 2018-01-29.

What is company current share price?

Current share price is 43.365 USD.

What is stock market cap today?

The market cap of stock today is 5347890620.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 373.